Eloxx Pharmaceuticals, Inc. (ELOX) News

Eloxx Pharmaceuticals, Inc. (ELOX): $0.33

0.05 (+18.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ELOX News Items

ELOX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ELOX News From Around the Web

Below are the latest news stories about Eloxx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ELOX as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday!

William White on InvestorPlace | December 20, 2021

Eloxx Pharmaceuticals (NASDAQ:ELOX) Now Covered by Oppenheimer

Investment analysts at Oppenheimer began coverage on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a note issued to investors on Thursday, Price Targets.com reports. The brokerage set an outperform rating and a $4.00 price target on the stock. Oppenheimers price target suggests a potential upside of 441.27% from the stocks previous close. ELOX has been the []

Transcript Daily | December 18, 2021

Millennium Management LLC Makes New Investment in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)

Millennium Management LLC acquired a new position in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 393,703 shares of the companys stock, valued at approximately $783,000. Millennium Management LLC owned approximately 0.82% of Eloxx Pharmaceuticals at the end of the []

Transcript Daily | December 13, 2021

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Expected to Announce Earnings of -$0.12 Per Share

Analysts expect that Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) will announce ($0.12) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Eloxx Pharmaceuticals earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.11). Eloxx Pharmaceuticals posted earnings per share of ($0.15) in the same []

Transcript Daily | December 11, 2021

State Street Corp Sells 248,516 Shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)

State Street Corp reduced its holdings in shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) by 56.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 189,203 shares of the companys stock after selling 248,516 shares during the quarter. State Street Corps holdings in []

Transcript Daily | December 8, 2021

Eloxx Shares Slump As Phase 2 Cystic Fibrosis Trial Data Fails To Cheer Investors

Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) posted topline results from the monotherapy arms of its Phase 2 trial of ELX-02 in Class 1 cystic fibrosis patients with at least one G542X nonsense allele mutation. Eloxx delivered one-week ELX-02 data on 12 people with a G542X nonsense mutation who received ELX-02 at 1.5 mg/kg/day. Sweat chloride, a biomarker of cystic fibrosis, fell by 5.4 mmol/L in recipients of ELX-02, causing the trial to meet one of its key secondary endpoints. However, there was n

Yahoo | November 17, 2021

Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02 monotherapy results support advancement of ELX-02 into Phase 3 clinical development First patient dosed in Phase 2 ELX-02 expansion treatment arms evaluating combination with ivacaftor; topline data expected by the end of the first half of 2022 Company to host conference call and webcast Wednesday, N

Yahoo | November 17, 2021

Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update

Data from Monotherapy Arms of Ongoing Phase 2 ELX-02 Cystic Fibrosis (CF) Clinical Trials Expected in Fourth Quarter of 2021 Received FDA Fast Track Designation for ELX-02 for the Treatment of CF Patients with Nonsense Mutations Hosted Call and Webcast on CF Programs Featuring CF Expert Dr. Eitan Kerem Appointed Ali Hariri, M.D. as Chief Medical Officer Entered into Senior Debt Facility from Hercules Capital for Borrowings of Up to $30 Million WATERTOWN, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) --

Yahoo | November 9, 2021

11 Best Penny Stocks To Buy According To Hedge Funds

In this article, we discuss the 11 best penny stocks to buy according to hedge funds. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Penny Stocks To Buy According To Hedge Funds. Hedge funds do not normally invest in penny stocks, primarily because of the risk […]

Yahoo | October 15, 2021

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | October 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4691 seconds.